Introduction to the APO-go ® Pump
Continuous dopaminergic stimulation (CDS) is a therapeutic strategy in Parkinson's that can reduce motor complications and improve overall quality of life.
The APO-go® drug is administered via a short and extremely fine needle into the subcutaneous fatty tissue of the abdominal area, to the right and left and under the level of the umbilicus. Alternatively you can use the upper, outer aspects of the thighs and arms. By administering the drug into the subcutaneous tissue (fatty layer under the skin), almost 100% of the drug is absorbed into the blood stream. This method of administration helps your Parkinson's disease specialist work towards giving you maximum control of your Parkinson’s disease.
What are the benefits of receiving a continuous infusion with APO-go®?
APO-go continuous infusion is used when a patient's symptoms are not sufficiently controlled by their oral medication. Generally it is used for 14-16 hours a day, during a person's waking day, but can sometimes be used at night if you experience poor quality sleep or night time cramps.
How big is the APO-go® Pump?
The APO-go® Pump used to supply continuous infusion of APO-go® has been specially designed to be small and discreet – smaller than most mobile phones.
Pump dimensions - 75mm x 45mm x 28mm (without syringe attached)
Lightweight, (weighing 135g with full 10ml syringe attached)
Portable – APO-go® Pump can be worn on the waistband of trousers/skirts or easily hidden under clothing.
The APO-pod is now available to help protect the pump, and is a discreet looking case that can be clipped onto a belt or worn using a lanyard.
What are the possible side effects of APO-go® continuous infusion therapy?
continuous infusion can cause nausea and vomiting as well as low blood pressure. Nausea doesn’t affect everyone, is very temporary and usually only occurs when APO-go®
continuous infusion therapy is first initiated. Domperidone, an anti-sickness medication, is always used with APO-go®
initiation to avoid nausea and discontinued with a few weeks of starting when it is no longer needed.
Nodule formation occurs in some patients using APO-go®. The formation of nodules is usually not a significant problem, but occasionally, if severe, can lead to erratic absorption of the drug and may affect the therapeutic outcome. Any nodule formation can be improved with strict rotation of the injection site used and improved skin care routine.
Is APO-go® continuous infusion therapy complicated?
The APO-go® Pump is easy to operate and set up, and you will be taught how to do this.
For most patients, a full day’s treatment can be set up without the need to add extra APO-go® later on – enabling you to set the Pump up in the morning and then forget about it and get on with your daily activities. In an APO-go® continuous infusion study, 75% of patients managed the Pump independently or with some help from their family or carer – no nursing help was needed.